Entropy Technologies’s Vir Biotechnology VIR Stock Holding History

Entropy Technologies’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,573	Closed	-$112K	–	938
2024 Q2	$112K	Buy	+12,573	New	+$121K	0.01%	628

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Entropy Technologies's VIR Position: Q3 2024 in Review

Entropy Technologies sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 12,573 shares — an estimated $112K sold.

Entropy Technologies first reported a position in VIR in Q2 2024 and held it in 1 quarter. The position peaked at $112K in Q2 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

Entropy Technologies reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
Entropy Technologies sold 12,573 Vir Biotechnology shares in Q3 2024, an estimated $112K.
Entropy Technologies first reported a position in Vir Biotechnology in Q2 2024 and held it in 1 quarter.
Entropy Technologies's Vir Biotechnology position peaked at $112K in Q2 2024.
197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Entropy Technologies's 13F filing for Q3 2024, filed 4 Nov 2024.